FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burde	en
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

affirmative defense 10b5-1(c). See Inst						
Name and Address of Reporting Person* Henrich Jill			2. Issuer Name and Ticker or Trading Symbol Atara Biotherapeutics, Inc. [ATRA]		tionship of Reporting Personal all applicable) Director	on(s) to Issuer
(Last) C/O ATARA BIO	ATARA BIOTHERAPEUTICS, INC.		3. Date of Earliest Transaction (Month/Day/Year) 08/16/2023	X	Officer (give title below) EVP, Global Head	Other (specify below)
2380 CONEJO SPECTRUM STREET, SUITE 200 (Street) THOUSAND CA 91320		T, SUITE 200	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv	(Check Applicable Line) orting Person one Reporting Person	
OAKS (City)	(State)	(Zip)				

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
		Code	v	Amount	Amount (A) or Price (D)		Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	08/16/2023	S ⁽¹⁾		2,788	D	\$1.653(2)	108,249	D	
Common Stock	08/16/2023	S ⁽¹⁾		558	D	\$1.654(2)	107,691	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	 3A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr. 8)		Derivative		Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		

Explanation of Responses

- 1. Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.
- 2. The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2023 and August 17, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee.

/s/ Jeff Kiekhofer, Attorney-in-Fact for Jill Henrich

08/18/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.